Marc Rubin's most recent trade in Curis Inc was a trade of 26,667 Common Stock done . Disclosure was reported to the exchange on March 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Curis Inc | Marc Rubin | Director | 20 Mar 2026 | 26,667 | 28,108 (0%) | 0% | - | Common Stock | ||
| Curis Inc | Marc Rubin | Director | 20 Mar 2026 | 20 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 26,667 | 26,667 | - | - | Series C Warrant (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 26,667 | 26,667 | - | - | Series B Warrant (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 26,667 | 26,667 | - | - | Series A Warrant (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 20 | 20 | - | - | Series B Convertible Preferred Stock | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 14,400 | 14,400 | - | - | Non Qualified Stock Option | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 1,600 | 1,600 | - | - | Non Qualified Stock Option | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,250 | 4,250 | - | - | Non Qualified Stock Option | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 85,000 | 85,000 | - | - | Non Qualified Stock Option | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 85,000 | 85,000 | - | - | Non Qualified Stock Option | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Titan Pharma Inc (de) | Marc Rubin | Director, Executive Chairman | 05 Jan 2022 | 65,000 | 65,000 | - | - | Option to Purchase Common Stock |